Alzamend Neuro Inc (ALZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
(Values in U.S. thousands)
| 04-2026 | 04-2025 | 04-2024 | 04-2023 | 04-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,772 | -4,515 | -9,948 | -14,878 | -12,362 |
| Depreciation Amortization | 111 | 51 | 51 | 23 | 4 |
| Other Working Capital | -114 | -2,439 | 671 | 2,349 | 1,327 |
| Other Operating Activity | 708 | 335 | 956 | 3,583 | 4,417 |
| Operating Cash Flow | $-8,068 | $-6,568 | $-8,270 | $-8,923 | $-6,614 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -300 | -147 | N/A | -107 |
| Investing Cash Flow | $N/A | $-300 | $-147 | $N/A | $-107 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 300 | N/A | N/A |
| Debt Repayment | N/A | N/A | N/A | N/A | -59 |
| Common Stock Issued | 795 | 2,704 | 1,252 | N/A | 6,000 |
| Other Financing Activity | 4,035 | 7,737 | 2,100 | 0 | 12,914 |
| Financing Cash Flow | $4,830 | $10,441 | $3,652 | $0 | $18,855 |
| Beginning Cash Position | 3,949 | 376 | 5,141 | 14,064 | 1,929 |
| End Cash Position | 711 | 3,949 | 376 | 5,141 | 14,064 |
| Net Cash Flow | $-3,238 | $3,573 | $-4,765 | $-8,923 | $12,135 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,068 | -6,568 | -8,270 | -8,923 | -6,614 |
| Capital Expenditure | N/A | -300 | -147 | N/A | -107 |
| Free Cash Flow | -8,068 | -6,868 | -8,417 | -8,923 | -6,721 |